Search

Displaying results 7861 - 7870 of 9886 in total
  1. Drug

    Seladelpar

    go.drugbank.com/drugs/DB12390
    ApprovedInvestigational

    Seladelpar is a peroxisome proliferator-activated receptor (PPAR)-delta (δ) agonist. Seladelpar is a single enantiomer of the R-configuration. … [L51149] On August 14, 2024, seladelpar was granted accelerated approval by the FDA for the treatment of primary biliary cholangitis,[L51154] which is a condition associated with aberrant bile acid metabolism

  2. Drug

    Remimazolam

    go.drugbank.com/drugs/DB12404
    ApprovedInvestigational

    [A214857] These "soft drugs" are useful in the context of surgical procedures, wherein a rapid onset/offset is desirable, enabling anesthesiologists to manipulate drug concentrations as needed.

  3. Drug

    Alvespimycin

    go.drugbank.com/drugs/DB12442
    Investigational

    Alvespimycin is a derivative of geldanamycin and heat shock protein (HSP) 90 inhibitor. It has been used in trials studying the treatment of solid tumor in various cancer as an antitumor agent.

  4. Drug

    Fedratinib

    go.drugbank.com/drugs/DB12500
    ApprovedInvestigational

    Fedratinib, also known as SAR302503 and TG101348, is a tyrosine kinase inhibitor used to treat intermediate-2 and high risk primary and secondary myelofibrosis.

  5. Drug

    Omaveloxolone

    go.drugbank.com/drugs/DB12513
    ApprovedInvestigational

    Omaveloxolone (RTA-408) is a semisynthetic oleanane triterpenoid with antioxidant and anti-inflammatory properties. … Therefore, the use of Nrf2 activators such as omaveloxolone represents a therapeutic advantage in this group of patients.

  6. Drug

    Asciminib

    go.drugbank.com/drugs/DB12597
    ApprovedInvestigational

    Asciminib is a tyrosine kinase inhibitor (TKI) used in the treatment of chronic-phase Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). … More specifically, it is an inhibitor of the ABL1 kinase activity of the BCR-ABL1 fusion protein[L38995] which serves as a driver of CML proliferation in most patients with the disease.

  7. Drug

    Sisomicin

    go.drugbank.com/drugs/DB12604
    Investigational

    Sisomicin has been used in trials studying the treatment of Pyoderma.

    Synonyms: -L-ARABINOPYRANOSYL)-D-STREPTAMINE, -L-ARABINOPYRANOSYL)-6-O-(2,6-DIAMINO-2,3,4,6-TETRADEOXY-.ALPHA.-D-GLYCERO-HEX-4-ENOPYRANOSYL)-L-STREPTAMINECategories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index
  8. Drug

    Plazomicin

    go.drugbank.com/drugs/DB12615
    Approved

    Developed by Achaogen biopharmaceuticals, plazomicin is a next-generation aminoglycoside synthetically derived from [DB12604].

    Categories: Drugs that are Mainly Renally Excreted with a Narrow Therapeutic Index
  9. Drug

    Amuvatinib

    go.drugbank.com/drugs/DB12742
    Investigational

    Amuvatinib also suppresses Rad51 protein, a critical component of double-stranded DNA repair in cancer cells.

    Synonyms: 1-Piperazinecarbothioamide, N-(1,3-benzodioxol-5-ylmethyl)-4-benzofuro(3,2-d)pyrimidin-4-yl-, 4-[1]Benzofuro[3,2-D]Pyrimidin-4-Yl-N-(1,3-Benzodioxol-5-Ylmethyl)Piperazine-1-Carbothioamide
  10. Drug

    Gabexate

    go.drugbank.com/drugs/DB12831
    Investigational

    Gabexate is a synthetic serine protease inhibitor which has been used as an anticoagulant. It also known to decrease production of inflammatory cytokines.